1. Home
  2. ENPH vs RYTM Comparison

ENPH vs RYTM Comparison

Compare ENPH & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Enphase Energy Inc.

ENPH

Enphase Energy Inc.

HOLD

Current Price

$45.14

Market Cap

5.9B

Sector

Technology

ML Signal

HOLD

Logo Rhythm Pharmaceuticals Inc.

RYTM

Rhythm Pharmaceuticals Inc.

HOLD

Current Price

$109.08

Market Cap

5.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ENPH
RYTM
Founded
2006
2008
Country
United States
United States
Employees
2872
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.9B
5.8B
IPO Year
2011
2017

Fundamental Metrics

Financial Performance
Metric
ENPH
RYTM
Price
$45.14
$109.08
Analyst Decision
Hold
Strong Buy
Analyst Count
23
14
Target Price
$41.30
$131.14
AVG Volume (30 Days)
6.4M
985.9K
Earning Date
04-28-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
72.00
28.34
EPS
N/A
N/A
Revenue
$1,472,985,000.00
N/A
Revenue This Year
N/A
$55.34
Revenue Next Year
$9.81
$86.06
P/E Ratio
N/A
N/A
Revenue Growth
10.72
N/A
52 Week Low
$25.78
$74.50
52 Week High
$73.74
$122.20

Technical Indicators

Market Signals
Indicator
ENPH
RYTM
Relative Strength Index (RSI) 43.31 60.84
Support Level $41.24 $98.30
Resistance Level $46.87 $113.03
Average True Range (ATR) 3.66 4.86
MACD -0.53 0.24
Stochastic Oscillator 29.38 63.85

Price Performance

Historical Comparison
ENPH
RYTM

About ENPH Enphase Energy Inc.

Enphase Energy is a global energy technology company. It delivers smart, easy-to-use solutions that manage solar generation, storage, and communication on one platform. The company's microinverter technology primarily serves the rooftop solar market and produces a fully integrated solar-plus-storage solution. Enphase derives a majority of revenue from the United States.

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.

Share on Social Networks: